N/A
Manufactured by Obagi Cosmeceuticals LLC
1,310 FDA adverse event reports analyzed
Last updated: 2026-04-15
HYDROQUINONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Obagi Cosmeceuticals LLC. The most commonly reported adverse reactions for HYDROQUINONE include SQUAMOUS CELL CARCINOMA OF SKIN, FATIGUE, DRUG INEFFECTIVE, PAIN, PRURITUS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for HYDROQUINONE.
Out of 559 classified reports for HYDROQUINONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,310 FDA FAERS reports that mention HYDROQUINONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include SQUAMOUS CELL CARCINOMA OF SKIN, FATIGUE, DRUG INEFFECTIVE, PAIN, PRURITUS, PRODUCT USE IN UNAPPROVED INDICATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Obagi Cosmeceuticals LLC in connection with HYDROQUINONE. Always verify the specific product and NDC with your pharmacist.